Croma (Croma-Pharma® GmbH) is a global player and challenger in the dynamically growing minimally invasive aesthetics market and a leading European manufacturer of premium quality hyaluronic acid (HA) syringes. The company offers a comprehensive and innovative aesthetics portfolio including botulinum toxin, fillers, PDO threads and biostimulators complemented by its own skincare brand.
Founded in 1976 by pharmacist couple Gerhard and Karin Prinz in Vienna, Croma is a family company headquartered in Austria where it also operates its hyaluronic acid (HA) syringe manufacturing plant. With 550 employees, 15 subsidiaries in Europe and Brazil, two joint ventures and 60 exclusive export partners, it distributes its products in 80 markets globally, including the US/Canada, China and Australia/New Zealand. Croma also operates as a hyaluronic acid contract manufacturer for orthopaedics and ophthalmology.
Today, the founders’ son, Andreas Prinz, manages the business as chief executive officer (CEO), together with Peter Haidenek, chief financial officer (CFO).